New cocktail therapy targets rare cancer after standard treatment fails
NCT ID NCT07518602
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a combination of three drugs—chidamide, sintilimab, and bevacizumab—in 34 people with advanced extrapulmonary neuroendocrine carcinoma that has worsened after first-line therapy. The goal is to see if this combo can shrink tumors or slow disease progression. Participants receive the drugs orally and intravenously over several weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Chidamide (oral drug), Sintilimab (immunotherapy), Bevacizumab (anti-angiogenic drug)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced extrapulmonary neuroendocrine carcinoma who have run out of standard options.
- What could go wrong
- This is a small, early-phase trial (34 people) with no control group, so results may not be definitive. The drug combination may cause side effects like immune-related reactions or bleeding risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.